Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Orexin Antagonism to Target Mechanisms of Suicide Risk: A Proof-of-Concept Clinical Trial

NCT06854224 is registered in ClinicalTrials.gov with Marianne Goodman as lead sponsor.

NCT NCT06854224
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06854224 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Orexin Antagonism to Target Mechanisms of Suicide Risk: A Proof-of-Concept Clinical Trial
Lead sponsor
Marianne Goodman
Phase
Phase 2
Overall status
Recruiting
Start date
September 1, 2025
Completion date
July 1, 2027
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder (mdd), suicide risk